编者按：慢性髓系白血病（CML）是白血病中进展相对缓慢的一种类型。然而一旦疾病进展至急变期，患者的预后将急剧恶化。最近20多年，一系列靶向疗法的涌现正帮助CML患者延长生命。作为全球医药创新的赋能者，药明康德一直以来依托“一体化、端到端”的CRDMO ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

After being diagnosed with chronic myeloid leukemia, graphic designer Aaron von Freter was able to participate in a clinical trial that offered him hope of being cured. When Aaron von Freter learned ...

MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...